ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
pi065509
|
107 |
28K |
8 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
107
|
28K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
pi065509
|
107 |
28K |
3 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
107
|
28K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
pi065509
|
107 |
28K |
9 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
107
|
28K
|
9
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
pi065509
|
107 |
28K |
13 |
26/07/24 |
26/07/24 |
ASX - By Stock
|
107
|
28K
|
13
|
|
ASX - By Stock
|
NUZ |
Re:
Pharmaust - Media & News
|
|
pi065509
|
259 |
90K |
19 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
259
|
90K
|
19
|
|
ASX - By Stock
|
NUZ |
Re:
Pharmaust - Media & News
|
|
pi065509
|
259 |
90K |
23 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
259
|
90K
|
23
|
|
ASX - By Stock
|
NUZ |
Re:
Pharmaust - Media & News
|
|
pi065509
|
259 |
90K |
36 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
259
|
90K
|
36
|
|
ASX - By Stock
|
NUZ |
Re:
Pharmaust - Media & News
|
|
pi065509
|
259 |
90K |
17 |
25/07/24 |
25/07/24 |
ASX - By Stock
|
259
|
90K
|
17
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
pi065509
|
107 |
28K |
20 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
107
|
28K
|
20
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Completes Share Purchase Plan
|
|
pi065509
|
107 |
28K |
19 |
24/07/24 |
24/07/24 |
ASX - By Stock
|
107
|
28K
|
19
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Investor Briefings & Webinar Notice
|
|
pi065509
|
81 |
24K |
5 |
16/07/24 |
16/07/24 |
ASX - By Stock
|
81
|
24K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Investor Briefings & Webinar Notice
|
|
pi065509
|
81 |
24K |
10 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
81
|
24K
|
10
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Monepantel Selected for Entry into HEALEY ALS Platform Trial
|
|
pi065509
|
64 |
19K |
9 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
64
|
19K
|
9
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Monepantel Selected for Entry into HEALEY ALS Platform Trial
|
|
pi065509
|
64 |
19K |
3 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
64
|
19K
|
3
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Monepantel Selected for Entry into HEALEY ALS Platform Trial
|
|
pi065509
|
64 |
19K |
22 |
15/07/24 |
15/07/24 |
ASX - By Stock
|
64
|
19K
|
22
|
|
ASX - By Stock
|
GFS |
Re:
Still Registered
|
|
pi065509
|
17 |
8.2K |
0 |
14/07/24 |
14/07/24 |
ASX - By Stock
|
17
|
8.2K
|
0
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
7 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
978
|
280K
|
7
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
14 |
11/07/24 |
11/07/24 |
ASX - By Stock
|
978
|
280K
|
14
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
13 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
978
|
280K
|
13
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
21 |
04/07/24 |
04/07/24 |
ASX - By Stock
|
978
|
280K
|
21
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
13 |
26/06/24 |
26/06/24 |
ASX - By Stock
|
978
|
280K
|
13
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Presentation
|
|
pi065509
|
91 |
25K |
13 |
24/06/24 |
24/06/24 |
ASX - By Stock
|
91
|
25K
|
13
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Presentation
|
|
pi065509
|
91 |
25K |
14 |
23/06/24 |
23/06/24 |
ASX - By Stock
|
91
|
25K
|
14
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Presentation
|
|
pi065509
|
91 |
25K |
15 |
23/06/24 |
23/06/24 |
ASX - By Stock
|
91
|
25K
|
15
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust Presentation
|
|
pi065509
|
91 |
25K |
16 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
91
|
25K
|
16
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
pi065509
|
159 |
42K |
5 |
21/06/24 |
21/06/24 |
ASX - By Stock
|
159
|
42K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
pi065509
|
159 |
42K |
2 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
42K
|
2
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
pi065509
|
159 |
42K |
8 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
42K
|
8
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
pi065509
|
159 |
42K |
7 |
20/06/24 |
20/06/24 |
ASX - By Stock
|
159
|
42K
|
7
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Trading Halt
|
|
pi065509
|
159 |
42K |
13 |
19/06/24 |
19/06/24 |
ASX - By Stock
|
159
|
42K
|
13
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
pi065509
|
284 |
82K |
3 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
284
|
82K
|
3
|
|
ASX - By Stock
|
CHM |
Re:
Ann: Notice of Extraordinary General Meeting/Proxy Form
|
|
pi065509
|
284 |
82K |
1 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
284
|
82K
|
1
|
|
ASX - By Stock
|
NUZ |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
pi065509
|
49 |
12K |
3 |
11/06/24 |
11/06/24 |
ASX - By Stock
|
49
|
12K
|
3
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
pi065509
|
58 |
15K |
2 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
58
|
15K
|
2
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
BIG FREEZE - CHILLS AND THRILLS
|
|
pi065509
|
58 |
15K |
1 |
10/06/24 |
10/06/24 |
ASX - By Stock
|
58
|
15K
|
1
|
|
ASX - By Stock
|
NUZ |
Re:
STRIKE Trial - Phase 2 / 3 - The final frontier to commercial outcome
|
|
pi065509
|
49 |
12K |
15 |
08/06/24 |
08/06/24 |
ASX - By Stock
|
49
|
12K
|
15
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: OLE Study update reveals impressive Survival Data
|
|
pi065509
|
248 |
71K |
7 |
07/06/24 |
07/06/24 |
ASX - By Stock
|
248
|
71K
|
7
|
|
ASX - By Stock
|
NUZ |
Re:
Pipeline-in-a-drug
|
|
pi065509
|
61 |
13K |
13 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
61
|
13K
|
13
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
7 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
978
|
280K
|
7
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
11 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
978
|
280K
|
11
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Executive team strengthened, appointment of MD/CEO & new CSO
|
|
pi065509
|
85 |
23K |
13 |
31/05/24 |
31/05/24 |
ASX - By Stock
|
85
|
23K
|
13
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
|
|
pi065509
|
978 |
280K |
9 |
20/05/24 |
20/05/24 |
ASX - By Stock
|
978
|
280K
|
9
|
|
ASX - By Stock
|
NUZ |
Re:
PAA TOP HOLDERS MOVEMENTS AS AT 30 APRIL 2024
|
|
pi065509
|
20 |
8.5K |
10 |
19/05/24 |
19/05/24 |
ASX - By Stock
|
20
|
8.5K
|
10
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: PharmAust appoints Sergio Duchini as Non-Executive Chairman
|
|
pi065509
|
58 |
17K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
58
|
17K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Investor update
|
|
pi065509
|
86 |
23K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
23K
|
5
|
|
ASX - By Stock
|
NUZ |
Re:
Ann: Investor update
|
|
pi065509
|
86 |
23K |
5 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
86
|
23K
|
5
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Great Pharmaust FDA ODD Approval Sweepstake
|
|
pi065509
|
222 |
53K |
4 |
17/05/24 |
17/05/24 |
ASX - By Stock
|
222
|
53K
|
4
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
392K |
6 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
392K
|
6
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
392K |
7 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
392K
|
7
|
|
ASX - By Stock
|
NUZ Biotech |
Re:
The Final Charge , Phase I/II MND Results & FDA ODD Approval Catalyst
|
|
pi065509
|
1.4K |
392K |
5 |
16/05/24 |
16/05/24 |
ASX - By Stock
|
1.4K
|
392K
|
5
|
|